Search academic texts

Information × Registration Number 0216U001464, 0114U001064 , R & D reports Title To investigate the efficacy of radionuclide therapy samarium 153Sm oksabiforom metastatic bone lesions in malignant tumors of different localization popup.stage_title Head Solodyannikova Oksana Ivanovna, Registration Date 16-02-2016 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 Purpose - to improve treatment and to determine the place of radionuclide therapy with samarium oksabiforom, 153Sm in the treatment of metastatic bone lesions in malignant tumors of various localization. Methods and apparatus - scan the entire body with 99mTc-DP, scan the entire body of Samaria 153Sm oksabiforom dynamic scintigraphy of Samaria 153Sm oksabiforom, statistics; dvohdetektorna gamma camera company "Mediso" (Hungary), single photon emission computed tomography (SPECT) "E. CAM 180 ". Found that radionuclide therapy with 153Sm-oksabiforom can be used in treatment of metastatic lesions of bone malignant tumors of various localization. Found that 153Sm-oksabifor high levels in metastatic accumulation RPF fire with minimal side effects. Before treatment intensity of pain (according to a scale "LAKOMED") meets 7-9 scores in most patients. After the treatment of pain intensity was 2.4 points. Tolerability of the drug meets the estimated scale scores 3 - good (there are minor adverse effects that do not require discontinuation of therapy). The most effective compared with 32P and 89Sr in the treatment of bone metastases by analgesic effect and tolerability is 153Sm oksabifor (p <0.05). The feature angiograms of 153Sm-oksabiforom with bone metastases, steadily accumulating RFP is reduced descending segment or no segment rising and crossing right in plateaus or slowly rising segment, due to fixation of the radiopharmaceutical metastatic foci in the first pass bolus through the vascular bed. The value of the coefficient Cp fixation on angiogram of 153Sm-oksabiforom derived from bone metastases, above 75-80% may indicate a high enough accumulation of RFP in metastatic foci rate and efficiency of radionuclide therapy Dynamic curves "activity-time", built from cells of bone metastases that accumulate radiopharmaceutical, usually have upward character, can speed recovery curves indicates the effectiveness of a course of radionuclide therapy. According to initial pharmacokinetics 153Sm-oksabifora, scanning of the entire body to assess the prevalence of the process is the best in 1-1,5 hours later after intravenous injection of the radiopharmaceutical. Product Description popup.authors Даниленко Вікторія Вікторівна Джужа Дмитро Олександрович Міхайленко Валерій Євгенович Сукач Георгій Георгійович popup.nrat_date 2020-04-02 Close